Loading…
Suraksha Diagnostic (SURAKSHA)₹350.40+1.96%Healthcare Service Provider
In the Jun 2026 quarter (consolidated), Suraksha Diagnostic reported sales of ₹87.82 Cr, up 20.6% from Jun 2025, and net profit of ₹12.99 Cr, up 44.5% year on year. For the year to Mar 2026, sales were ₹309 Cr and net profit ₹30.98 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 59.87 | 51.92 | 54.93 | 60.91 | 66.91 | 59.87 | 64.94 | 72.83 | 78.86 | 77.84 | 80.85 | 87.82 |
| Expenses | 38.84 | 35.88 | 35.90 | 39.88 | 43.89 | 40.87 | 45.87 | 48.85 | 54.82 | 54.81 | 56.86 | 56.85 |
| Operating Profit | 21.02 | 15.03 | 19.04 | 21.02 | 23.02 | 18.02 | 19.04 | 24.06 | 24.04 | 23.03 | 24.04 | 30.06 |
| OPM % | 35.0% | 30.0% | 35.0% | 34.0% | 35.0% | 31.0% | 29.0% | 33.0% | 31.0% | 30.0% | 30.0% | 35.0% |
| Other Income | 0.99 | 0.99 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
| Interest | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 3.01 | 3.01 | 3.01 | 4.01 | 4.01 |
| Depreciation | 8.02 | 8.03 | 8.02 | 9.03 | 9.02 | 9.02 | 9.02 | 9.03 | 10.03 | 11.02 | 11.03 | 11.03 |
| Profit before tax | 11.02 | 6.01 | 9.02 | 11.02 | 14.04 | 8.01 | 9.01 | 12.01 | 12.02 | 10.02 | 10.02 | 17.03 |
| Tax % | 24.0% | 27.1% | 32.1% | 27.0% | 26.1% | 26.0% | 22.1% | 26.1% | 27.0% | 28.1% | 38.1% | 22.1% |
| Exceptional items | 0.00 | 0.00 | −0.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 7.99 | 4.99 | 5.99 | 8.01 | 9.99 | 6.01 | 6.99 | 8.99 | 9.01 | 6.99 | 5.99 | 12.99 |
| EPS (Rs) | 122.16 | 67.53 | 94.61 | 1.85 | 2.41 | 1.19 | 1.43 | 1.81 | 1.74 | 1.45 | 1.22 | 2.51 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 158 | 140 | 223 | 190 | 219 | 252 | 309 | 325 |
| Expenses | 123 | 115 | 173 | 142 | 146 | 170 | 214 | 223 |
| Operating Profit | 34.09 | 25.02 | 49.07 | 47.06 | 73.16 | 82.18 | 95.16 | 101 |
| OPM % | 22.0% | 18.0% | 22.0% | 25.0% | 33.0% | 33.0% | 31.0% | 31.1% |
| Other Income | 1.99 | −0.99 | 0.99 | 0.99 | 0.99 | 3.99 | 2.99 | 3.96 |
| Interest | 2.01 | 2.01 | 2.01 | 10.01 | 10.02 | 9.02 | 13.02 | 14.04 |
| Depreciation | 13.03 | 16.05 | 15.04 | 32.09 | 33.09 | 35.09 | 41.11 | 43.11 |
| Profit before tax | 21.04 | 6.01 | 33.06 | 7.01 | 31.08 | 41.05 | 45.08 | 49.09 |
| Tax % | 28.0% | −1.0% | 28.0% | 10.1% | 26.1% | 25.1% | 30.1% | — |
| Exceptional items | 0.23 | −1.70 | −1.02 | −1.17 | −2.05 | −0.20 | 0.00 | 0.00 |
| Net Profit | 14.99 | 5.99 | 24.01 | 6.01 | 22.99 | 30.99 | 30.98 | 34.98 |
| EPS (Rs) | 220.96 | 93.46 | 344.88 | 94.65 | 342.89 | 6.13 | 6.19 | 6.92 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 6.97 | 6.98 | 6.97 | 6.98 | 6.99 | 9.97 | 9.96 |
| Reserves | 111 | 118 | 141 | 147 | 171 | 201 | 234 |
| Borrowings | 13.04 | 18.04 | 21.07 | 99.36 | 92.27 | 89.23 | 130 |
| Other Liabilities | 42.10 | 28.14 | 32.13 | 28.10 | 30.14 | 33.05 | 73.11 |
| Total Liabilities | 173 | 171 | 201 | 282 | 301 | 335 | 449 |
| Fixed Assets | 128 | 119 | 119 | 195 | 212 | 223 | 316 |
| CWIP | 0.00 | 0.00 | 1.01 | 2.01 | 1.01 | 11.02 | 35.07 |
| Investments | 5.01 | 5.01 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 |
| Other Assets | 39.13 | 46.15 | 80.28 | 84.25 | 87.36 | 99.38 | 97.34 |
| Inventories | 5.46 | 4.46 | 6.24 | 6.17 | 6.69 | 8.06 | 8.15 |
| Trade receivables | 6.02 | 6.02 | 7.60 | 4.70 | 8.91 | 13.87 | 22.86 |
| Cash & equivalents | 3.91 | 4.42 | 2.81 | 54.92 | 54.93 | 20.07 | 26.28 |
| Total Assets | 173 | 171 | 201 | 282 | 301 | 335 | 449 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 31.07 | 24.06 | 42.08 | 44.05 | 60.06 | 63.15 | 82.19 |
| Cash from investing activity | −19.98 | −27.95 | −43.91 | −20.95 | −34.96 | −39.93 | −51.91 |
| Cash from financing activity | −9.99 | 2.99 | 1.01 | −23.99 | −24.99 | −24.02 | −28.99 |
| Net cash flow | 0.99 | −0.99 | 0.00 | −0.99 | 0.00 | 0.00 | 0.99 |
| Capex | 16.05 | 15.05 | 19.05 | 13.03 | 45.16 | 42.13 | 67.22 |
| Free cash flow | 14.95 | 7.98 | 22.93 | 31.87 | 17.95 | 20.94 | 14.94 |
| CFO / OP % | 111.0% | 100.1% | 95.0% | 109.1% | 95.0% | 90.1% | 100.1% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 14 | 16 | 12 | 9 | 15 | 20 | 27 |
| Inventory days | 93 | 62 | 38 | 82 | 89 | 100 | 81 |
| Days payable | 227 | 177 | 84 | 187 | 193 | 169 | 209 |
| Cash conversion cycle | −119 | −98 | −33 | −95 | −88 | −48 | −100 |
| Working capital days | −36 | −20 | −16 | −50 | −38 | −24 | −29 |
| ROCE % | — | 8.0% | 24.0% | 9.1% | 17.1% | 18.1% | 17.0% |
For the Jun 2026 quarter, Suraksha Diagnostic reported sales of ₹87.82 Cr, up 20.6% year on year and net profit of ₹12.99 Cr, up 44.5% year on year. The operating margin was 35.0%.
Suraksha Diagnostic's sales for the year to Mar 2026 were ₹309 Cr; over the last twelve months they were ₹325 Cr.
Net profit for the year to Mar 2026 was ₹30.98 Cr, and ₹34.98 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.92.
Suraksha Diagnostic reported borrowings of ₹130 Cr at Mar 2026, against cash and equivalents of ₹26.28 Cr.
Cash from operations was ₹82.19 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹14.94 Cr.